YMYusuke Mori

Yusuke Mori

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yusuke Mori has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Early parathyroid hormone elevation after denosumab therapy following parathyroidectomy: a diagnostic pitfall

    by Hiroyuki Yamashita, Hisakazu Shindo, Daisuke Tatsushima, Yusuke Mori, Kento Katsuyama, Shinya Sato

    Persistently elevated parathyroid hormone (PTH) after parathyroidectomy is often attributed to residual disease but may reflect altered calcium (Ca) homeostasis. The impact of denosumab on perioperative PTH interpretation remains unclear. A 77-year-old woman presented with a hypercalcemic crisis and was initially managed at another hospital. During treatment with hydration and elcatonin (40 units twice daily), denosumab (60 mg) was administered, resulting in a rapid decline in corrected Ca (c-Ca). Eleven days later, at presentation to our institution, her c-Ca was 9.9 mg/dL (SI: 2.48 mmol/L; reference range, 8.8-10.1 mg/dL [SI: 2.20-2.53 mmol/L]), and intact PTH was 195 pg/mL (SI: 20.7 pmol/L; reference range, 10-65 pg/mL [SI: 1.1-6.9 pmol/L]). At admission, c-Ca decreased further while PTH increased. The patient had chronic kidney disease and vitamin D deficiency. A focused parathyroidectomy was performed for a single adenoma. Thirty minutes after excision, PTH remained above the surgical success threshold and increased further the morning after surgery, while c-Ca levels decreased. Calcium and vitamin D supplementation subsequently normalized both parameters. Denosumab exposure, together with vitamin D deficiency and renal impairment, may cause transient postoperative PTH elevation despite successful parathyroidectomy. Persistent disease should not be assumed when Ca declines despite elevated PTH.

  • Impact of antithyroid drug duration on radioactive iodine therapy efficacy in Graves’ disease in Japan: a propensity score-matched analysis using thyroid weight-based outcomes

    by Seigo Tachibana, Tomoyuki Ohara, Yuji Nagayama, Takashi Fukuda, Daisuke Tatsushima, Yusuke Mori, Hisakazu Shindo, Hiroshi Takahashi, Shinya Sato, Hiroyuki Yamashita

    Radioactive iodine therapy (RAIT) is an established treatment option for Graves’ disease (GD). In Japan, antithyroid drugs (ATDs) are typically first-line therapy, with RAIT or thyroidectomy reserv...

  • Open Access

    Primary hyperparathyroidism unmasking after dienogest-altered estrogen dynamics: implications for calcium homeostasis

    by Hiroyuki Yamashita, Daisuke Tatsushima, Hisakazu Shindo, Yusuke Mori, Kento Katsuyama, Shinya Sato

    Normocalcemic primary hyperparathyroidism (PHPT) is increasingly recognized as an early or indeterminate disease form. Although estrogen is believed to modulate calcium homeostasis, its role in progression to overt PHPT remains incompletely understood. A parathyroid adenoma was suspected in a 33-year-old woman despite normal calcium and parathyroid hormone (PTH) levels. At 37 years of age, approximately 6 months after starting dienogest 0.5 mg twice daily for menorrhagia, she developed prolonged amenorrhea and improved anemia. The PTH level subsequently increased from 38 to 57 pg/mL (SI: 4.0-6.0 pmol/L) (reference range 10-65 pg/mL [SI: 1.1-6.9 pmol/L]) with mild hypercalcemia (corrected calcium, 10.3 mg/dL [SI: 2.58 mmol/L]) (reference range, 8.8-10.1 mg/dL [SI: 2.20-2.53 mmol/L]). Despite the prolonged amenorrhea, her estradiol levels were not suppressed. The dienogest was discontinued preoperatively and menstruation resumed; however, the hypercalcemia and elevated PTH persisted. Imaging revealed the parathyroid adenoma. Upon its resection, the PTH level promptly normalized. Altered estrogen dynamics rather than an absolute estrogen deficiency may have contributed to the transition to overt PHPT noted herein. Manifested hypercalcemia is not readily reversible, suggesting a shift to a self-sustaining state. This case raises the possibility that altered hormonal dynamics may contribute to the manifestation of PHPT.

  • Serum free triiodothyronine as an adjunctive marker for thyroid hormone status in athyreotic patients on levothyroxine

    by Yuji Nagayama, Seigo Tachibana, Takashi Fukuda, Daisuke Tatsushima, Yusuke Mori, Hisakazu Shindo, Hiroshi Takahashi, Shinya Sato, Masahiro Nakashima, Hiroyuki Yamashita

    Context: Athyreotic patients receiving levothyroxine (LT4) for hypothyroidism sometimes exhibit low serum free triiodothyronine (FT3) levels despite normal TSH, and experience hypothyroid-like symptoms and signs, suggesting reduced peripheral thyroid hormone action. Objective: The present study aimed to identify the most reliable biochemical marker for assessing peripheral thyroid hormone status in such patients. Methods: This was a single-center retrospective, cross-sectional study of athyreotic patients on LT4. Patients were classified according to TSH, FT3 and FT4, and selected metabolic markers potentially influenced by peripheral thyroid hormone status were compared across groups. Results: In 426 athyreotic patients taking ≥1.2 μg/kg of LT4, the majority (58%) of patients exhibited normal serum FT3 and FT4, followed by 21% with normal FT3 and elevated FT4, 18% with low FT3 and normal FT4, and 2% with low FT3 and elevated FT4. This classification corresponded well with the differences in FT3/FT4 ratios that reflect the efficiency of T4 to T3 conversion. Among 156 patients not taking anti-hyperlipidemic drugs and selected with the propensity score matching using gender as a covariate, the metabolic markers of alanine transaminase, and body mass index were significantly elevated in those with low FT3 than in those with normal FT3. Conclusion: In our cohort, lower FT3 was associated with selected metabolic markers in LT4-treated athyreotic patients, suggesting that FT3 may provide additional information on peripheral thyroid hormone status in selected patients. Prospective studies with standardized sampling and adjustment for confounding are warranted to establish FT3 as a validated marker or support FT3-guided dosing.

  • Open Access

    Multiple thyroid cysts: a benign and stable clinical entity based on longitudinal data

    by Yuji Nagayama, Seigo Tachibana, Takashi Fukuda, Daisuke Tatsushima, Yusuke Mori, Hisakazu Shindo, Hiroshi Takahashi, Shinya Sato, Hiroyuki Yamashita

    Multiple thyroid cysts are commonly detected by ultrasonography, and are considered clinically insignificant. On the other hand, polycystic thyroid disease (PCTD) has been proposed as a cause of antibody-negative hypothyroidism in iodine-replete regions; however, the clinical characteristics and natural history of multiple thyroid cysts as a broader entity remain unclear. To elucidate these issues, we retrospectively reviewed 7,727 consecutive new outpatients at a high-volume thyroid center between 2013 and 2016. Multiple thyroid cysts were defined as ≥4 cysts (≥3 mm in diameter) in the absence of thyroid autoantibodies. Among all patients, 164 (2.1%) met the criteria. The mean age was 58.3 years, and 91.0% were female. At presentation, 86.6% were euthyroid, 6.1% and 6.7% had subclinical hypothyroidism and subclinical hyperthyroidism, respectively, and one patient had Graves’ disease. Thus, approximately 6% of multiple thyroid cysts may be PCTD. Forty-six patients were followed up for ≥5 years (mean 9.8 years) without iodine restriction. Thyroid function remained stable in most cases, with no significant progression to overt dysfunction and no requirement for surgical or interventional treatment. Ultrasonographic findings ranged from numerous diffuse cysts throughout the gland to several scattered or localized cysts. Some cysts remained stable, some increased, and others decreased in size in the follow-up periods. The cyst distribution patterns (diffuse versus localized) were not associated with thyroid function. Therefore, multiple thyroid cysts may generally represent benign and stable clinical entities, supporting conservative management with periodic monitoring in most patients.

  • Open Access

    Early predictors of 6-month thyroid-stimulating antibody levels after radioactive iodine therapy for Graves’ disease: implications for pregnancy planning

    by Seigo Tachibana, Yuji Nagayama, Takashi Fukuda, Yusuke Taguchi, Daisuke Tatsushima, Yusuke Mori, Hisakazu Shindo, Hiroshi Takahashi, Shinya Sato, Hiroyuki Yamashita

    Current guidelines recommend a 6-month contraception period following radioactive iodine therapy (RAIT) for Graves’ disease (GD), based primarily on radiation safety considerations; however, they do not account for the post-treatment surge in thyroid-stimulating antibodies (TSAb), which poses risks for fetal and neonatal GD. This retrospective study aimed to identify factors influencing TSAb trajectories and construct a predictive model for TSAb levels at 6 months after RAIT. We analyzed 82 patients who underwent RAIT, with TSAb values standardized to the upper limit of normal (ULN) to account for different assay methods. Multivariable linear regression identified the duration of antithyroid drug and potassium iodide administration, pre-RAIT TSAb levels, changes in TSAb at 3 months (3M), fractional reduction in TW at 3M, and assay method as significant predictors of TSAb levels at 6 months (adjusted R2 = 0.87). A prediction score derived from this model demonstrated excellent diagnostic performance. Receiver operating characteristic analysis yielded an area under the curve of 0.99 for predicting TSAb >3.3 ULN, corresponding to the threshold for fetal GD monitoring at approximately 20 weeks of gestation, and 0.94 for TSAb >1.0 ULN. The prediction score significantly outperformed single predictors, including baseline TSAb levels and early post-TSAb changes. In conclusion, we developed a highly accurate predictive model for TSAb levels at 6 months after RAIT by integrating early post-treatment data with pre-RAIT clinical parameters. This model enables identification of patients at risk of persistent TSAb elevation, supporting individualized counseling regarding pregnancy planning beyond the conventional 6-month contraception period.

  • Development of painless thyroiditis after thyroid lobectomy in patients with Hashimoto’s thyroiditis

    by Shinya Sato, Yuji Nagayama, Hisakazu Shindo, Kento Katsuyama, Daisuke Tatsushima, Yusuke Mori, Hiroshi Takahashi, Seigo Tachibana, Takashi Fukuda, Hiroyuki Yamashita

    Postoperative hypothyroidism, a complication of thyroid lobectomy, occurs frequently. Unique cases of post-lobectomy painless thyroiditis, a pathology not previously reported, were recently observed in our practice. In this study, we aimed to retrospectively investigate the frequency and characteristics of thyroid dysfunction after lobectomy, focusing on painless thyroiditis. A total of 193 patients with thyroid tumors, including 66 with Hashimoto's thyroiditis and 127 without Hashimoto's thyroiditis, underwent thyroid lobectomy. These patients were followed up for 49.6 (12-118) months. Thyroid dysfunction occurred in 20.7% of patients, including 31.8% (21/66) and 14.9% (19/127) of those with and without Hashimoto's thyroiditis, respectively. The types of thyroid dysfunction included thyrotoxicosis (10.0%), subclinical hypothyroidism (47.5%), and overt hypothyroidism (42.5%). Nine of 21 patients with Hashimoto's thyroiditis who developed thyroid dysfunction 1-4 months after lobectomy were diagnosed with painless thyroiditis, based on the characteristic transient hypoechogenic pattern on ultrasonography during hormonal fluctuations. Four patients developed thyrotoxicosis, one of whom subsequently become hypothyroid. Thyroid function returned to normal in all four patients. Two patients tested negative for TSH receptor antibody during the thyrotoxic period. The remaining five patients developed hypothyroidism, which was transient in three patients. Painless thyroiditis develops as post-lobectomy thyroid dysfunction in patients with Hashimoto's thyroiditis. We propose naming this condition "post-lobectomy thyroiditis," as it is believed to be triggered by surgical manipulation of the thyroid gland in individuals with underlying subclinical thyroid autoimmunity. Given its transient nature in most cases, distinguishing this condition from postoperative permanent hypothyroidism is essential.


  • Acute Transient Thyroid Cracking: A Proposal of a New Disease Entity as a Mild Form of Acute Transient Thyroid Swelling

    by Yuji Nagayama, Hisakazu Shindo, Seigo Tachibana, Takashi Fukuda, Kento Katsuyama, Daisuke Tatsushima, Yusuke Mori, Hiroshi Takahashi, Shinya Sato, Hiroyuki Yamashita

    Objective: This study aims to investigate the clinical and ultrasonographic features of thyroid swelling following fine-needle aspiration biopsy (FNAB), and to distinguish between symptomatic and asymptomatic forms.Methods: We retrospectively reviewed 872 patients who underwent thyroid ultrasonography before and after FNAB between January and November 2024. Patients showing new hypoechoic cracking after FNAB were identified. Clinical symptoms, degree of thyroid swelling, and outcomes were evaluated.Results: Hypoechoic cracking developed in 18 patients (2.1%), appearing immediately in 17 and at 4 hours in one. Three patients (17%) experienced symptoms such as pain or compression, all with thyroid swelling exceeding 1.8-fold the original size. The remaining 15 patients were asymptomatic, with swelling less than 1.5-fold. No clinical characteristics were significantly associated with the development of symptoms. All patients recovered spontaneously; two symptomatic cases received steroid treatment.Conclusion: Post-FNAB thyroid swelling can be classified into two entities: typical, symptomatic acute transient thyroid swelling (ATTS) and a newly proposed asymptomatic form, acute transient thyroid cracking (ATTC). Recognizing ATTC as a mild, self-limiting condition is important for avoiding unnecessary treatment and alleviating patient concern.

  • Open Access

    Synchronous cancers including parathyroid carcinoma with urinary calculus as the initial sign

    by Yoshihiro Kawaguchi, Mitsunori Matsuo, Naoki Ito, Yusuke Mori, Shinichi Maekawa, Shingo Tsuneyoshi, Yusuke Okayama, Hidehiro Ishii, Tsukasa Igawa

    Hyperparathyroidism with urinary calculus as the initial symptom is common; however, carcinomas of the parathyroid gland are rare. Moreover, synchronous cancers have rarely been reported. A man in his 50s presented to our hospital with a 1-month history of left lumbar back pain. After close examination, urinary calculus, parathyroid carcinoma, and lung cancer were detected. He underwent surgical treatment followed by additional anticancer drugs. Two and a half years following his first visit to our hospital, no recurrence has been observed. Parathyroid carcinoma should be considered as a cause of urinary calculus, and synchronous cancers, including rare cancer, can also exist.

  • Open Access

    Paradoxical Elevation of Parathyroid Hormone Levels following Preoperative Native Vitamin D Supplementation in a Patient with Graves’ Disease Undergoing Total Thyroidectomy: A Case Report

    by Hiroyuki Yamashita, Hisakazu Shindo, Yusuke Mori, Daisuke Tatsushima, Takashi Fukuda, Seigo Tachibana, Hiroshi Takahashi, Yuji Nagayama, Shinya Sato

    INTRODUCTION: Hypocalcemia is a common complication after total thyroidectomy, particularly in patients with Graves’ disease and high bone turnover. Preoperative vitamin D deficiency is a known risk factor for postoperative hypocalcemia; however, the effects of vitamin D supplementation remain controversial. This is the first study to document a paradoxical increase in parathyroid hormone (PTH) levels after preoperative vitamin D supplementation in a patient undergoing total thyroidectomy.CASE PRESENTATION: We report the case of a 68-year-old woman with Graves’ disease and coexisting thyroid cancer who received native vitamin D (2000 IU/day) for 4 weeks before surgery. This unexpectedly resulted in a marked increase in PTH levels and bone formation markers, suggesting the worsening of secondary hyperparathyroidism. Interestingly, fibroblast growth factor 23 levels remained unchanged despite an increase in PTH and 1,25-dihydroxyvitamin D levels. Postoperatively, she developed transient hypoparathyroidism.CONCLUSIONS: Native vitamin D supplementation may, paradoxically, worsen secondary hyperparathyroidism in some patients, highlighting the need for careful preoperative metabolic assessment and individualized management strategies.